-
1.发明授权Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity 有权具有β2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性的二烷基苯基化合物公开(公告)号：US07687521B2
公开(公告)日：2010-03-30
申请号：US12406283
申请日：2009-03-18
IPC分类号： A61K31/445
CPC分类号： C07D211/46
摘要： This invention relates to compounds of formula I: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
摘要翻译： 本发明涉及式I化合物：其中R1和R2如本说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明还涉及包含这些化合物的药物组合物和组合物，用于制备这些化合物的方法和中间体，以及使用该化合物例如治疗慢性阻塞性肺疾病和哮喘等肺病的方法。
-
公开(公告)号：US08618131B2
公开(公告)日：2013-12-31
申请号：US13545523
申请日：2012-07-10
IPC分类号： A61K31/47 , C07D215/00
CPC分类号： C07D211/46 , A61K31/445 , A61K31/452 , C07D211/48 , C07D211/58 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/06 , C07D409/12 , C07D453/02 , C07D471/08 , G01N33/9433
摘要： This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthmas.
摘要翻译： 本发明提供式I的联苯衍生物：其中R1，R2，R3，R4，R5，R6，R7，W，a，b和c如说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明的联苯衍生物具有β2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性，因此，这种联苯衍生物可用于治疗肺部疾病，如慢性阻塞性肺病和哮喘。
-
公开(公告)号：US20130323271A1
公开(公告)日：2013-12-05
申请号：US13905338
申请日：2013-05-30
申请人： Mathai Mammen , Adam D. Hughes
发明人： Mathai Mammen , Adam D. Hughes
IPC分类号： C07C233/56 , A61K31/42 , C07D271/04 , C07D413/12 , A61K31/4245 , A61K31/216 , C07D261/18 , A61K45/06
CPC分类号： C07D271/08 , A61K31/216 , A61K31/42 , A61K31/4245 , A61K45/06 , C07C233/56 , C07C235/80 , C07C243/28 , C07D261/18 , C07D271/04 , C07D413/12
摘要： In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donors and have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中R1，R2，R3，R7，R8，Z，X，b和c如说明书中所定义，或其药学上可接受的盐。 这些化合物是一氧化氮供体并且具有去甲肾上腺素抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
4.发明申请DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY 失效具有BETA2 ADRENERGIC受体激动剂和MUSCARINIC受体拮抗剂活性的二烷基苯酚化合物公开(公告)号：US20100137603A1
公开(公告)日：2010-06-03
申请号：US12701108
申请日：2010-02-05
IPC分类号： C07D405/12 , C07D211/44
CPC分类号： C07D211/46
摘要： This invention relates to compounds of formula I: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
摘要翻译： 本发明涉及式I化合物：其中R1和R2如本说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明还涉及包含这些化合物的药物组合物和组合物，用于制备这些化合物的方法和中间体，以及使用该化合物例如治疗慢性阻塞性肺疾病和哮喘等肺病的方法。
-
5.发明申请DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY 有权具有BETA2 ADRENERGIC受体激动剂和MUSCARINIC受体拮抗剂活性的二烷基苯酚化合物公开(公告)号：US20090176833A1
公开(公告)日：2009-07-09
申请号：US12406283
申请日：2009-03-18
IPC分类号： A61K31/445 , A61P11/06
CPC分类号： C07D211/46
摘要： This invention relates to compounds of formula I: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
摘要翻译： 本发明涉及式I化合物：其中R1和R2如本说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明还涉及包含这些化合物的药物组合物和组合物，用于制备这些化合物的方法和中间体，以及使用该化合物例如治疗慢性阻塞性肺疾病和哮喘等肺病的方法。
-
公开(公告)号：US09045443B2
公开(公告)日：2015-06-02
申请号：US13905338
申请日：2013-05-30
申请人： Mathai Mammen , Adam D. Hughes
发明人： Mathai Mammen , Adam D. Hughes
IPC分类号： C07D261/18 , C07D413/12 , C07D271/08 , C07C235/80 , A61K31/42 , A61K31/4245 , A61K31/216 , C07C233/56 , A61K45/06 , C07D271/04 , C07C243/28
CPC分类号： C07D271/08 , A61K31/216 , A61K31/42 , A61K31/4245 , A61K45/06 , C07C233/56 , C07C235/80 , C07C243/28 , C07D261/18 , C07D271/04 , C07D413/12
摘要： In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donors and have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中R1，R2，R3，R7，R8，Z，X，b和c如说明书中所定义，或其药学上可接受的盐。 这些化合物是一氧化氮供体并且具有去甲肾上腺素抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
7.发明授权Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity 有权具有β2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性的二烷基苯基化合物公开(公告)号：US07524965B2
公开(公告)日：2009-04-28
申请号：US11789300
申请日：2007-04-24
IPC分类号： C07D211/40 , A61K31/445
CPC分类号： C07D211/46
摘要： This invention relates to compounds of formula I: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
摘要翻译： 本发明涉及式I化合物：其中R1和R2如本说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明还涉及包含这些化合物的药物组合物和组合物，用于制备这些化合物的方法和中间体，以及使用该化合物例如治疗慢性阻塞性肺疾病和哮喘等肺病的方法。
-
8.发明授权Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity 失效具有二肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性的二烷基苯基化合物公开(公告)号：US08134006B2
公开(公告)日：2012-03-13
申请号：US12701108
申请日：2010-02-05
IPC分类号： C07D211/00
CPC分类号： C07D211/46
摘要： This invention relates to compounds of formula I: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
摘要翻译： 本发明涉及式I化合物：其中R1和R2如本说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明还涉及包含这些化合物的药物组合物和组合物，用于制备这些化合物的方法和中间体，以及使用该化合物例如治疗慢性阻塞性肺疾病和哮喘等肺病的方法。
-
9.发明申请Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity 有权具有β2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性的二烷基苯基化合物公开(公告)号：US20070249675A1
公开(公告)日：2007-10-25
申请号：US11789300
申请日：2007-04-24
IPC分类号： A61K31/445 , C07D211/40
CPC分类号： C07D211/46
摘要： This invention relates to compounds of formula I: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐或溶剂化物或立体异构体，其中R 1和R 2和R 2如说明书中所定义。 本发明还涉及包含这些化合物的药物组合物和组合物，用于制备这些化合物的方法和中间体，以及使用该化合物例如治疗慢性阻塞性肺疾病和哮喘等肺病的方法。
-
公开(公告)号：US09593110B2
公开(公告)日：2017-03-14
申请号：US14608686
申请日：2015-01-29
IPC分类号： C07D249/04 , C07D231/14 , C07D263/34 , C07D271/07 , C07D213/81 , A61K31/422 , A61K31/4192 , A61K31/4196 , A61K31/42 , A61K31/4245 , C07D471/04 , C07D261/18 , C07D249/10 , A61K31/415 , A61K31/421 , A61K31/44 , C07D239/28 , A61K31/505 , C07D275/03 , A61K31/425 , A61K31/437 , C07D403/04 , A61K31/4985 , C07D403/12 , A61K45/06 , C07D405/14 , C07D309/40 , C07C271/22 , C07D319/06 , C07D231/18 , C07D231/20 , C07D233/70 , C07D233/90 , C07D401/04 , C07D235/08 , C07D403/06 , C07D237/14 , C07D239/34 , C07D405/12 , C07C229/34 , C07D249/12 , C07D249/18 , C07D261/12 , C07D263/18 , C07D295/10
CPC分类号： C07D249/04 , A61K31/415 , A61K31/4192 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/425 , A61K31/437 , A61K31/44 , A61K31/4985 , A61K31/505 , A61K45/06 , A61P9/04 , A61P9/12 , A61P13/12 , C07C229/34 , C07C271/22 , C07D213/81 , C07D231/14 , C07D231/18 , C07D231/20 , C07D233/70 , C07D233/90 , C07D235/08 , C07D237/14 , C07D239/28 , C07D239/34 , C07D249/10 , C07D249/12 , C07D249/18 , C07D261/12 , C07D261/18 , C07D263/18 , C07D263/34 , C07D263/38 , C07D271/07 , C07D275/03 , C07D295/10 , C07D309/40 , C07D319/06 , C07D401/04 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/04
摘要： In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
摘要翻译： 一方面，本发明涉及具有式I的化合物：其中R 1 -R 6如说明书中所定义，或其药学上可接受的盐。 这些化合物具有去血清抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
-
-
-
-
-
-
-
-
搜索结果
74 条记录 (耗时 0.042 秒)
